Skip to main content

Table 1 Baseline characteristics of RA patients and controls

From: Impaired myocardial perfusion in rheumatoid arthritis is associated with impaired strain, strain rate, disease activity and myocardial oedema: a cardiovascular magnetic resonance study

  Controls N=55 RA N=55 P value
Female sex, n (%) 39 (71) 39 (71) 1.00
Age, years 53 ± 10 54 ± 11 0.70
Hypertension, n(%) 4 (7) 9 (16) 0.24
Diabetes, n(%) 0 3 (5) -
Hyperlipidaemia, n(%) 11 (20) 9 (16) 0.75
BMI, kg/m2 24 ± 4 26 ± 4 0.06
Methotrexate, n(%) N/A 50 (91) -
Chloroquine, n(%) N/A 30 (55) -
Leflunomide, n(%) N/A 10 (18) -
Sulfasalazine, n(%) N/A 8 (15) -
Rituximab, n(%) N/A 3 (5) -
Prednisolone, n(%) N/A 5 (9) -
DAS28-CRP N/A 3.4 ± 1.4 -
ESR, mm/hr (median, IQR) N/A 13 (8-17) -
CRP, mg/L (median, IQR) 1 (1-2) 10 (5-16) <0.001
Duration of RA, years (median, IQR) N/A 9 (5-13) -
Duration of DMARDs, years (median, IQR) N/A 6 (3-8) -
RF positive, n (%) N/A 45 (82) -
ACCP positive, n (%) N/A 38 (69) -
  1. Continuous data are mean ± SD unless otherwise indicated.
  2. Categorical data are frequency (percent) unless otherwise indicated.
  3. ACCP, anti-cyclic citrullinated peptide antibodies; BMI, body mass index; CRP, C-reactive protein; DAS28-CRP, rheumatoid arthritis disease activity index incorporating 28 tender and swollen joint count and serum CRP; DMARD, disease modifying anti-rheumatic drug(s); ESR, erythrocyte sedimentation rate; IQR, interquartile range; RA, rheumatoid arthritis; RF, rheumatoid factor